Ontology highlight
ABSTRACT: Introduction
The randomized, open-label, assessor-blinded, parallel-group SPIRIT-H2H trial (NCT03151551) demonstrated superiority of ixekizumab over adalimumab in simultaneously achieving improvement in joint symptoms (American College of Rheumatology [ACR]50) and skin clearance (Psoriasis Area and Severity Index [PASI]100) in biologic-naïve patients with active psoriatic arthritis (PsA) and plaque psoriasis (PsO) at Week (W) 24. Higher efficacy of ixekizumab versus adalimumab was maintained through W52.Objectives
This analysis investigated efficacy and safety of ixekizumab and adalimumab in the subgroup of patients with PsA and moderate-to-severe PsO through W52.Methods
Efficacy and safety outcomes were analyzed in patients with PsA and moderate-to-severe PsO (PASI
SUBMITTER: Reich K
PROVIDER: S-EPMC9116563 | biostudies-literature | 2022 May
REPOSITORIES: biostudies-literature